Quoin Pharmaceuticals, Ltd. (QNRX) Research

Quoin Pharmaceuticals, Ltd. operates as a specialized pharmaceutical firm, concentrating its efforts on devising therapeutic solutions for rare and orphan medical conditions. Its flagship offering, QRX003, is a topical lotion specifically formulated to address Netherton Syndrome. Furthermore, the company is advancing QRX004 for the management of dystrophic epidermolysis bullosa, alongside QRX006, a prospective therapy for an additional rare dermatological ailment. The organization maintains its operational base in Ashburn, Virginia.

Market snapshot

Symbol
QNRX
Price
$4.65
Day change
+0.65%
Market cap
$9.3M
P/E ratio
-0.78x
52-week range
4.1-41.8
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months

Peer companies

  • Cyclerion Therapeutics, Inc. (CYCN)
  • Pasithea Therapeutics Corp. (KTTA)
  • NovaBay Pharmaceuticals, Inc. (NBY)
  • Polyrizon Ltd. (PLRZ)
  • PharmaCyte Biotech, Inc. (PMCB)
  • Radiopharm Theranostics Limited (RADX)
  • Alaunos Therapeutics, Inc. (TCRT)
  • VivoSim Labs, Inc. (VIVS)

Recent insider activity

  • Stonepine Capital Management, LLC — trade (0 shares) on 2026-03-26
  • Lawlor Sally Bridget — A-Award (85250 shares) on 2026-02-04
  • Cooper Joseph Patrick — A-Award (8141 shares) on 2026-02-04
  • Culverwell Anthony James — A-Award (21709 shares) on 2026-02-04
  • Myers Michael — A-Award (318750 shares) on 2026-02-04

Open Quoin Pharmaceuticals, Ltd. (QNRX) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.